Multi-resistant Candida Species: A Global Public Health Problem: A Systematic Review
DOI:
https://doi.org/10.56294/piii2023162Keywords:
Candida, Multidrug Resistance, Outbreak, Nosocomial, Susceptibility, Drug effectsAbstract
Background: Candida yeast infections are frequent in the hospital population. These fungi are part of the normal microbiota of the skin and mucous membranes of humans. Although almost 150 species are recognized in the genus, 90% of invasive processes are caused by Candida albicans, Candida glabrata, Candida tropicalis and Candida parapsilosis. Candida albicans continues to be the predominant species, although the frequency of non-albicans Candida (CNA) is increasing. These include the latter species with intrinsic resistance to fluconazole such as C.krusei (now known as Pichia kudriavzevii) or decreased resistance to fluconazole such as C glabrata and decreased resistance to echinocandins such as C parapsilosis. Candida auris has been reported as the causative agent of invasive infections in humans in at least 47 countries. It is transmitted through contact with contaminated environments or with colonized people. In November 2022, two cases of infection by this fungus were detected for the first time in Argentina. Material and methods: In this systematic review, 427 articles searched on platforms such as Pubmed, Google Scholar, and Epistemonikos were found, and 10 were used to carry them out. Results: The articles chosen study hospitalized patients in intensive care units who present candidemia due to multiresistant fungi. The results show us that therapeutic success is associated with the correct identification of fungi and antifungal susceptibilities tests. The vast majority of isolated cases showed resistance to at least one of the three main classes of antifungals. Conclusion: Nosocomial outbreaks due to multiresistant fungi present a high mortality rate associated with therapeutic failure due to the difficulty in identifying some fungi with routine techniques. It was also discovered that the comorbidities of each patient is a risk factor for infection. Finally, it was shown that the protocols for decontamination and cleaning of the patient and their environment, together with the isolation of positive patients, are effective in stopping horizontal transmission between patients
References
Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis : biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. marzo de 2012;36(2):288-305.
Nunes MBM, Batista LM, Pessoa WFB. Candida auris - uma ameaça para a saúde pública no Brasil: revisão narrativa Candida auris - a public health threat in Brazil: narrative review. . ISSN.
Rhodes J, Fisher MC. Global epidemiology of emerging Candida auris. Curr Opin Microbiol. diciembre de 2019;52:84-9.
Alp Ş, Arıkan Akdağlı S. Candida auris ve Antifungal İlaçlara Direnç Mekanizmaları. Mikrobiyol Bul. 27 de enero de 2021;55(1):99-112.
Carolus H, Pierson S, Muñoz JF, Suboti A, Dijck PV. Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance. 2021;12(2).
Tu J, Liu N, Huang Y, Yang W, Sheng C. Small molecules for combating multidrug-resistant superbug Candida auris infections. Acta Pharm Sin B. noviembre de 2022;12(11):4056-74.
Santana DJ, O’Meara TR. Forward and reverse genetic dissection of morphogenesis identifies filament-competent Candida auris strains. Nat Commun. 10 de diciembre de 2021;12(1):7197.
Kordalewska M, Lee A, Park S, Berrio I, Chowdhary A, Zhao Y, et al. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Antimicrob Agents Chemother. junio de 2018;62(6):e00238-18.
Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care. 2011;15(5):R253.
Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast. Clin Infect Dis. 6 de enero de 2018;66(2):306-11.
Ruiz Gaitán AC, Moret A, López Hontangas JL, Molina JM, Aleixandre López AI, Cabezas AH, et al. Nosocomial fungemia by Candida auris: First four reported cases in continental Europe. Rev Iberoam Micol. enero de 2017;34(1):23-7.
Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel. Emerg Infect Dis [Internet]. febrero de 2017 [citado 5 de junio de 2023];23(2). Disponible en: http://wwwnc.cdc.gov/eid/article/23/2/16-1486_article.htm
Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. febrero de 2015;41(2):285-95.
Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. junio de 2014;33(6):919-26.
Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, et al. New Clonal Strain of Candida auris , Delhi, India: New Clonal Strain of Candida auris , Delhi, India. Emerg Infect Dis. octubre de 2013;19(10):1670-3.
Khillan V, Rathore N, Kathuria S, Chowdhary A. A rare case of breakthrough fungal pericarditis due to fluconazole‐resistant Candida auris in a patient with chronic liver disease. JMM Case Rep [Internet]. 1 de septiembre de 2014 [citado 5 de junio de 2023];1(3). Disponible en: https://www.microbiologyresearch.org/content/journal/jmmcr/10.1099/jmmcr.0.T00018
Kim M, Shin JH, Sung H, Lee K, Kim E, Ryoo N, et al. Candida haemulonii and Closely Related Species at 5 University Hospitals in Korea: Identification, Antifungal Susceptibility, and Clinical Features. Clin Infect Dis. 15 de marzo de 2009;48(6):e57-61.
Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. diciembre de 2016;5(1):35.
Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris. J Clin Microbiol. septiembre de 2011;49(9):3139-42.
Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus—United States, May 2013–August 2016. Am J Transplant. enero de 2017;17(1):296-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Eliza Lima Vital, Susana Irma Carnovale (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
